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Abstract
Background: Overt hypothyroidism has been associated with arterial hypertension and increased
arterial stiffness. Results in euthyroid individuals have been conflicting. We investigated associations
of thyroid function with systolic (SAP) and diastolic (DAP) arterial pressure in euthyroid subjects.
Methods: 311 euthyroid individuals (185 women, mean age 43.9 ± 9) without a history of diabetes
attending a preventive medicine program were examined. Subjects receiving thyroxine (10.6%)
were excluded; 19.3% had hypertension, 43% had a family history for hypertension. TSH, fT4,
thyroid autoantibodies, insulin, glucose were measured. The "fT4.TSH product", which has been
suggested as a T4 resistance-index, was calculated.
Results: TSH range was 0.1–8, median 1.4 mU/L, fT4 range was 11.5–25.2 pmol/L, median 17.4.
TSH and the "fT4.TSH product" were positively associated with DAP (p < 0.03, for both
associations). In the subgroup of individuals with TSH levels 0.36–2.5 mU/L, both TSH and the
"fT4.TSH product" were positively correlated with SAP (r = +0.133 p = 0.044, r = +0.152 p = 0.026)
and DAP (r = +0.243 p < 0.001, r = +0.252 p < 0.001 respectively); in multivariate analysis the
"fT4.TSH product" was a significant predictor of DAP independently of HOMA-IR and BMI (p <
0.001). Similar associations were found when only the non-hypertensive subjects were analysed (p
= 0.004). Hypertensive patients had higher TSH levels (p = 0.02) and belonged more frequently to
the subgroup with TSH > 2 mU/L (35.3% vs 21.3%, p = 0.045).
Conclusion: In euthyroid individuals the association of thyroid function with diastolic arterial
pressure remains significant even when a stricter "normal range" for TSH levels is considered. The
"freeT4.TSH" product appears to be an even stronger predictor of DAP, independently of HOMA
insulin resistance index and obesity.
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Background
Thyroid hormones influence cardiovascular function
[1,2] and modulate the vascular response [3]. Overt
hypothyroidism may be associated with hypertension and
various adverse cardiovascular effects [4-9].
Subclinical hypothyroidism has also been associated with
arterial hypertension, mostly diastolic [10-12], as well as
with atherosclerosis [13,14] and coronary heart disease
[15,16] in both sexes. However these findings have not
been consistent. In overt and especially in subclinical
hypothyroidism normotensive patients are quite fre-
quently observed particularly in younger age groups [17-
20]. Thus the risk of mild thyroid failure for cardiovascu-
lar disease and, subsequently, the need for a therapeutic
intervention in this group, remain controversial [1,19,21].
It is interesting that such associations have also been
reported for euthyroid individuals. TSH variation within
the normal range has been associated with alterations in
various cardiovascular parameters including arterial pres-
sure [11,22,23] and lipid profile [11,24]. Early markers of
atherosclerosis such as increased intima media thickness
[25] and impaired endothelial function [26-28] may be
detected among patients with borderline thyroid func-
tion. It has further been reported that hypertensive
patients may have a tendency for impaired thyroid func-
tion [29]; however these results have not always been con-
firmed [20].
The mechanism through which slightly impaired thyroid
function might influence arterial blood pressure is not
clear; increased systemic vascular resistance, premature
atherosclerosis and increased arterial stiffness may all be
involved [2,30]. It has been argued that in the hypothy-
roid state, the sympathetic and the renin-angiotensin-
aldosterone systems are possibly implicated in the home-
ostasis of arterial pressure [31,32]. Thyroxine replacement
therapy may reverse the cardiovascular effects and may
result in the regulation of arterial pressure in subjects with
subclinical hypothyroidism [8,32-35]. However, it has
been suggested that the mechanisms involved in these
associations may not be attributed to impaired thyroid
hormone action; genetic factors alone may influence the
regulation of both arterial blood pressure and circulating
TSH levels as well as the individually determined set point
of thyroid function [28].
The purpose of our study was to investigate associations of
thyroid function parameters with systolic (SAP) and
diastolic (DAP) arterial pressure in clinically euthyroid
subjects.
Methods
We studied 311 euthyroid individuals (185 women, 126
men, mean age 43.9 ± 9) who visited the cardiovascular
laboratory in response to an announcement for free exam-
ination for unrecognized features of the metabolic syn-
drome in the outpatients' clinic of our hospital over a
period of 12 months. Thyroid function tests were
included in the protocol.
Exclusion criteria were a history of diabetes mellitus (pre-
viously diagnosed according to the American Diabetes
Association criteria), overt coronary heart disease or a pre-
vious history of stroke. The presence of hypertension was
defined as systolic and/or diastolic blood pressure higher
than 139 mmHg and/or 89 mmHg, respectively and/or
current use of antihypertensive drugs.
Patients receiving thyroxine as well as those who were on
drugs possibly affecting thyroid function such as lithium,
amiodarone or γ-interferon were excluded from the anal-
ysis (10.6%). Of the studied individuals included in the
analysis (165 women, 113 men) 19.3% had hypertension
and 43% had a family history for hypertension. The study
was approved by the institutional Ethics Committee and
all subjects gave their informed consent.
Using a standard mercury sphygmomanometer and after
5 minutes of rest, three consecutive measurements of arte-
rial pressure were obtained while all subjects were in a sit-
ting position and the mean was calculated. Height and
weight were also measured with subjects wearing indoor
clothes without shoes. Body mass index (BMI) was calcu-
lated according to the formula weight (kg)/height (m2).
Waist and hip perimeter (cm) measurements were per-
formed and waist to hip ratio (W/H R) was used to evalu-
ate fat distribution. Current drug therapy and clinical
history were also recorded. Ninety one (55.1%) of the
women participating in the study were premenopausal.
Fasting blood samples were obtained by venipuncture
between 08:00–09:00 h. Serum TSH and free thyroxine
were measured using chemiluminescent immunometric
assays with the DPC Immulite 200 (Siemens). Serum anti-
thyroid antibodies (antiTPO, antiTG) analysis was per-
formed by RIA using the reagents Brahms DINOtest
(Brahms diagnostica GmbH, Berlin). Reference range was:
TSH 0.36–4 mU/L, fT4 9–25 pmol/L, antiTPO < 60 IU/ml,
antiTG < 60 IU/ml. Data were also analysed using a TSH
cutoff of either 2 or 2.5 mU/L. Glucose levels (measured
immediately using an automated analyser Integra 400,
Roche) and insulin levels (in specimens kept frozen at -
20°C until analysis was performed by IRMA, Biosource
Europe SA, Nivelles, Belgium) were also estimated. Basal
insulin resistance index (Homeostasis Model Assessment,
HOMA) was calculated according to the formula: InsulinThyroid Research 2008, 1:3 http://www.thyroidresearchjournal.com/content/1/1/3
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resistance = FI × G/22.5, where FI = fasting insulin (μU/
ml) and G = fasting glucose (mmol/L).
The "fT4.TSH product", derived by multiplying TSH by
fT4, was calculated. Previous studies have suggested that
this index, referred to as T4 resistance-index, may deter-
mine the fT4-TSH set-point for each person. TSH appears
to contribute by 85% to the fT4.TSH variance [28,36].
Statistical analysis
Statistical analysis was done using the SPSS statistical
package. All descriptive data are presented as mean ± SD.
Linear regression analysis was used to investigate correla-
tions between continuous variables. In the multivariate
analysis we included as possible confounders all the vari-
ables for which there was some correlation which was sta-
tistically significant or which showed a tendency to be
significant in the univariate analysis. Student's t – test was
used to compare mean values between groups where the
distribution was normal. Chi – square test with Yates' con-
tinuity correction was used, or chi – square for linear asso-
ciation as appropriate.
Results
TSH range was 0.1–8, median 1.4 mU/L; fT4 range was
11.5–25.2, median 17.4 pmol/L. The clinical and bio-
chemical characteristics of the population are shown in
table 1.
TSH and the "fT4.TSH product" were positively associated
with diastolic arterial pressure (DAP) (r = +0.134, p =
0.029 and r = +0.156, p = 0.014 respectively). In the sub-
group of individuals with TSH levels 0.36–2.5 mU/L (n =
238), TSH levels were positively correlated with systolic (r
= +0.133, p = 0.04) and diastolic arterial pressure (r =
+0.243, p < 0.001, figure 1). Similarly, in the same sub-
group, the "fT4.TSH product" was positively correlated
with SAP (r = +0.152, p = 0.026) and DAP (r = +0.252, p
< 0.001, figure 2) respectively. A multivariate analysis
(step model) was performed considering associations of
DAP with age, sex, cardiovascular risk factors such as
HOMA-IR and BMI and thyroid function parameters. In
this model, the "fT4.TSH product" was a significant inde-
pendent predictor of DAP (table 2). The association of
DAP with TSH was no longer significant when age, BMI
and HOMA-IR were taken into account. Similarly, when
only the normotensive subjects with TSH levels 0.36–2.5
Table 1: Baseline characteristics of the studied population
%M e a n  ±  S D R a n g e
Sex (men) 40.5
Age (years) 43.9 ± 9 34.9–52.9
BMI 26.9 ± 4.7 19.0–43.3
Waist-to-hip Ratio 0.87 ± 0.12 0.52–1.39
Hypertension 19.3
Dyslipidemia 41
Family history of hypertension 43
Smoking 42
TSH (mU/L) 1.6 ± 1.01 0.1–8.0
fT4 (pmol/L) 17.8 ± 2.2 11.5–25.2
fT4.TSH product 26.4 ± 15.8 1.04–92
Systolic blood pressure (mmHg) 119.7 ± 20.3 85–195
Diastolic blood pressure (mmHg) 77.2 ± 12.3 55–120
HOMA-IR index 1.88 ± 1.4 0.4–11.0
Association of diastolic arterial blood pressure with TSH lev- els in the subgroup of apparently healthy subjects with TSH  levels in the narrow "normal range" (0.36–2.5 mU/L) (r =  +0.243, p < 0.001) Figure 1
Association of diastolic arterial blood pressure with 
TSH levels in the subgroup of apparently healthy sub-
jects with TSH levels in the narrow "normal range" 
(0.36–2.5 mU/L) (r = +0.243, p < 0.001).
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Association of diastolic arterial blood pressure with 
the "fT4.TSH product" in the subgroup of apparently 
healthy subjects with TSH in the narrow "normal 
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mU/L were analysed (n = 203), TSH levels and the
"fT4.TSH product" showed positive association with DAP
(r = +0.208, p = 0.004 and r = +0.212, p = 0.004 respec-
tively, Pearson's correlation).
Hypertensive patients had higher TSH levels (1.92 ± 1.04
vs 1.54 ± 1.3, p = 0.02, t-test) and belonged more fre-
quently to the subgroup with TSH > 2 mU/L compared to
normotensive ones (35.3% vs 21.3%, p = 0.045 x2-test).
Normotensive subjects with a family history for hyperten-
sion belonged more frequently to the subgroup with TSH
> 2 mU/L although this finding was not significant (p =
0.056, Pearson chi-square).
There were no significant differences in the occurrence of
hypertension in the patients with positive thyroid auto-
antibodies (either antiTG or antiTPO).
In the subgroup with subclinical hyperthyroidism (n = 17,
5.7%) there were no associations between TSH levels and
systolic and/or diastolic blood pressure.
Discussion
Our study has demonstrated that in euthyroid individuals
with TSH levels in the narrow "normal range" (0.36–2.5
mU/L), diastolic as well as systolic arterial blood pressure
is positively associated with TSH levels. These associations
remained significant even when only normotensive sub-
jects were considered. Similar positive associations have
also been reported by other investigators [11,12]. Asvold
et al [22] in a large population study which included more
than 30000 euthyroid subjects, found a positive linear
association between systolic and diastolic arterial pressure
and TSH levels. Furthermore, the fifth Tromso study
showed that systolic and diastolic blood pressure were
higher in euthyroid individuals belonging to the highest
versus the lowest serum TSH quartile of the normal range
[23]. On the other hand, in another recent community-
based study mean DAP and SAP did not differ between
individuals with subclinical hypothyroidism and euthy-
roid subjects [20]. Similarly, no such associations were
reported in other studies concerning either younger
[34,37] or older [14,17] individuals; however in these
studies there were significant associations of mild thyroid
failure with other cardiovascular parameters such as left
ventricular diastolic dysfunction [34] or atherosclerosis
and coronary heart disease [14,37].
We have further demonstrated that the "fT4.TSH product"
is also positively associated with diastolic as well as with
systolic blood pressure. This association was independent
of age, sex, insulin resistance and obesity. The same result
was found even when only normotensive subjects were
considered for the analysis. This marker has been rarely
used in the literature and may reflect an individually
determined fT4-TSH relationship [28,36]; it may not rep-
resent thyroid function but it may be indicative of an
altered sensitivity of peripheral tissues to thyroid hor-
mones. This means that higher TSH levels for a standard
value of freeT4 are associated with higher arterial blood
pressure and thus probably with impaired peripheral vas-
cular function [28]. There are no reports in the literature
for similar associations concerning arterial pressure.
Although the significance of this product cannot be clearly
defined, it is interesting that recently vascular indices have
again been associated with this marker. Fernandez-Real et
al reported significant associations of the same marker
with insulin sensitivity and endothelial function in euthy-
roid individuals [28]. In this study, patients with reduced
endothelium-dependent vasodilatation had "fT4.TSH
product" values above the median and also increased TSH
levels. Based on these results a hypothesis of possible
genetic variations which could influence vascular function
and serum TSH as well as the individually determined thy-
roid set point, might be supported [28,38].
Another finding in our study concerns the subjects with a
history of hypertension. Higher TSH levels were associ-
ated with a history of hypertension. Moreover, hyperten-
sive subjects belonged more frequently to the subgroup
with TSH > 2 mU/L. As we have previously shown, TSH
values above these levels, may be associated with
endothelial dysfunction [26] and increased arterial stiff-
ness [30] compared to euthyroid subjects with TSH levels
lower than 2 mU/L. Similar results have been reported in
the population study of Asvold et al [22]. They showed
that when subjects with TSH levels in the upper part of the
normal range (3–3.5 mU/L) were compared to those with
Table 2: Stepwise multiple regression model for predicting diastolic arterial pressure in apparently healthy individuals with TSH 0.36–
2.5 mU/L
Variable Predictor Beta T Significance P Overall R2 (%)
Diastolic arterial pressure Age 0.193 3.103 0.002 0.295
P < 0.001
Sex -0.222 -3.625 <0.001
HOMA-IR 0.203 2.705 0.007
BMI 0.167 2.154 0.032
"fT4.TSH product" 0.210 3.515 0.001Thyroid Research 2008, 1:3 http://www.thyroidresearchjournal.com/content/1/1/3
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TSH levels in the lower part of the normal range (0.5–0.99
mU/L), the odds ratio for hypertension in the former
group was 1.98 for men and 1.23 for women, respectively.
In another study, by Iqbal et al, TSH levels were higher
among individuals with diastolic hypertension [23].
Finally, Gumieniac et al showed that euthyroid hyperten-
sive subjects had slightly impaired thyroid function with
lower fT4 index and higher TSH levels compared to nor-
motensive subjects [29]. On the other hand Walsh et al
reported no differences in the prevalence of hypertension
in subjects with subclinical hypothyroidism compared to
euthyroid ones, after adjustment for age and sex [20]. In
another large study concerning an older population, no
differences were observed in the prevalence of hyperten-
sion, cardiovascular outcomes and mortality between the
overt hypothyroidism, subclinical hypothyroidism and
normal thyroid function groups [19]. In agreement with
other studies we did not find any associations between
thyroid autoantibody positivity and the presence of
hypertension [20].
Finally, normotensive individuals with a family history of
hypertension belonged more frequently to the subgroup
with TSH > 2 mU/L although this association just missed
statistical significance. A similar finding has been reported
by Gumieniac et al in a study of hypertensive families
[38]. In this study normotensive euthyroid subjects with a
family history of hypertension had higher TSH levels com-
pared to those with a negative history. In the same study,
a familial aggregation of high-normal TSH levels was
observed; these investigators speculated that there may be
common genetic variants which affect both the pituitary-
thyroid axis set point and the regulation of arterial pres-
sure. As it has been mentioned previously, "the fT4.TSH
product" could be a phenotypic marker of each individ-
ual's set point of thyroid function, probably genetically
determined. Thus, one might suggest that our results indi-
rectly concur with the observations reported by Fernan-
dez-Real et al [28] and by Gumieniac et al [38]. Studies in
spontaneously hypertensive rats have confirmed that arte-
rial pressure regulation is in part mediated by TRH [39];
similarly, polymorphic variants of genes such as the TSH
receptor gene or the type 2 iodothyronine deiodinase
genes could be implicated in both insulin resistance and
the regulation of arterial pressure and TSH levels [40,41].
We did not find associations between arterial pressure and
TSH at the lower levels of the normal range or with the
presence of subclinical hyperthyroidism. This could be
due to the small sample of subjects with subclinical hyper-
thyroidism. In the literature there are reports for such
associations [20,22] although these results are not consist-
ent [42].
A limitation of our results was the relatively small number
of studied individuals. However, several of our findings
point to the same direction.
Conclusion
In conclusion, in euthyroid individuals the associations of
thyroid function with arterial blood pressure remain sig-
nificant even when a stricter "normal range" for TSH levels
is considered. The "freeT4.TSH" product appears to be an
even stronger predictor of diastolic arterial blood pres-
sure, independently of HOMA insulin resistance index
and obesity.
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